Thanks to its over 14 years experience, Skuldtech has acquired expertise on gene expression by bioinformatic analysis. Hence, the company has developed proprietary bioinformatic programs and database for analyzing sequencing data.
Except for some particular cases which are now well-known, most recent medical improvements and studies have underlined that diseases and physiological adaptations are not linked to a single genetic modification occurring in a specific manner, but to complex routes associated with genetic networks, which interact with each other.
Understanding the complex interactions occurring between genetic networks is the key challenge to be met in the medical field over the next decade. In this aim, scientists worldwide have gathered an impressive amount of medical and biological data which need to be closely connected in order to provide a comprehensive overview of diseases. This comprehensive overview of medical disorders will enable to improve treatments within the field of Personalized Medicine and will help to design new drugs or treatments for serious diseases with significant unmet medical needs.
At the same time, high-performance computing applications have increasingly adopted new architecture–based servers. However, new sequencing technologies, producing DNA sequences, have also made huge progress. Today, these new high throughput sequencing systems provide a considerable amount of data which have to be processed by a high-performance computer.
Skuldtech develops private Bioinformatic platforms dedicated to genomic analysis and to the implementation of these data in pathways and clinical routes.
Regarding the expansion of high throughput sequencing methods such as Roche-454 (GsFlx), Illumina (1G sequencer) or Applied (SOLID), new tools are now available and they offer efficient approaches for rapidly sequencing DNA. As a result, generating sequencing data becomes very easy.
Therefore, bioinformatic programs and database are fully required for analyzing the results generated by the aforementioned high throughput systems, including sequence analysis, gene annotation, computational evolutionary biology, measuring biodiversity, analysis of regulation, analysis of protein expression, analysis of mutation in cancer, etc.
Within the quest for the $1,000 Human Genome, the bioinformatic platform of Skuldtech will be a key tool for comparing each patient with known data regarding medical disorders.
Skuldtech’s private bioinformatic platform is especially focused on genomic data management. This platform is based on twelve years of experience gained through the association of computational experts and biological experts.
Skuldtech’s private bioinformatic platform uses a fast processing speed and a large memory to rapidly assess very large databases and process acquired information.
Skuldtech is specialized in the discovery of
new Biomarkers and the development of Diagnostics
focused on personalized medicine applications.
This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics
associated with new treatments, especially in
cancer, neurodegenerative and infectious diseases.